CN103079563B - 作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物 - Google Patents

作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物 Download PDF

Info

Publication number
CN103079563B
CN103079563B CN201180040497.4A CN201180040497A CN103079563B CN 103079563 B CN103079563 B CN 103079563B CN 201180040497 A CN201180040497 A CN 201180040497A CN 103079563 B CN103079563 B CN 103079563B
Authority
CN
China
Prior art keywords
phenyl
pyrrolidine
methoxy
amide
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180040497.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103079563A (zh
Inventor
克里斯多夫·博斯
克莉丝汀·普罗奇
约翰·加特菲尔德
马库斯·盖得
比比安·海德曼
蒂埃里·西弗朗
约迪·T·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN103079563A publication Critical patent/CN103079563A/zh
Application granted granted Critical
Publication of CN103079563B publication Critical patent/CN103079563B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201180040497.4A 2010-08-24 2011-08-23 作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物 Expired - Fee Related CN103079563B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IB2010053799 2010-08-24
WOPCT/IB2010/053799 2010-08-24
IBPCT/IB2010/053799 2010-08-24
PCT/IB2011/053693 WO2012025877A1 (en) 2010-08-24 2011-08-23 Proline sulfonamide derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
CN103079563A CN103079563A (zh) 2013-05-01
CN103079563B true CN103079563B (zh) 2015-07-08

Family

ID=44658790

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180040497.4A Expired - Fee Related CN103079563B (zh) 2010-08-24 2011-08-23 作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物

Country Status (9)

Country Link
US (3) US8895606B2 (cg-RX-API-DMAC7.html)
EP (1) EP2608787B1 (cg-RX-API-DMAC7.html)
JP (1) JP5744203B2 (cg-RX-API-DMAC7.html)
KR (1) KR101802726B1 (cg-RX-API-DMAC7.html)
CN (1) CN103079563B (cg-RX-API-DMAC7.html)
CA (1) CA2807000C (cg-RX-API-DMAC7.html)
ES (1) ES2769607T3 (cg-RX-API-DMAC7.html)
TW (1) TW201209037A (cg-RX-API-DMAC7.html)
WO (1) WO2012025877A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
CN105793257B (zh) 2013-12-03 2018-11-13 爱杜西亚药品有限公司 苯并咪唑环化合物的晶形及其用途
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
WO2021207678A1 (en) * 2020-04-09 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Kappa opioid receptor antagonists for treating pain-related sleep disorders
EP4356909A1 (en) * 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822111B2 (ja) 1977-10-29 1983-05-06 協和醗酵工業株式会社 柑橘類果実の改質剤
JPS5581857A (en) 1978-12-15 1980-06-20 Kyowa Hakko Kogyo Co Ltd Modifier of citrus fruit
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
DE10035144A1 (de) 2000-07-19 2002-01-31 Merck Patent Gmbh Cyclische Aminosäurederivate
GB0225938D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
WO2004073634A2 (en) 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
EP1697337A2 (en) 2003-12-22 2006-09-06 Astellas Pharma Inc. Ornithine derivatives as prostaglandin-e2-agonists or antagonists
RU2378257C2 (ru) 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
EP2049526A2 (en) 2006-07-14 2009-04-22 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR101343399B1 (ko) * 2008-01-08 2013-12-19 퍼듀 퍼머 엘피 통증 치료를 위한 카나비노이드 수용체에 대한 리간드로서의 프롤린 유사체
CN101918361B (zh) * 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
ES2350548B1 (es) 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
ES2351323B1 (es) 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) 2009-07-01 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives

Also Published As

Publication number Publication date
CA2807000A1 (en) 2012-03-01
US9211279B2 (en) 2015-12-15
EP2608787A1 (en) 2013-07-03
CN103079563A (zh) 2013-05-01
US8895606B2 (en) 2014-11-25
JP5744203B2 (ja) 2015-07-08
WO2012025877A1 (en) 2012-03-01
US20150057328A1 (en) 2015-02-26
TW201209037A (en) 2012-03-01
KR101802726B1 (ko) 2017-11-29
CA2807000C (en) 2018-12-04
US20150246021A1 (en) 2015-09-03
KR20130110160A (ko) 2013-10-08
EP2608787B1 (en) 2019-11-20
US20130150424A1 (en) 2013-06-13
JP2013538206A (ja) 2013-10-10
ES2769607T3 (es) 2020-06-26
US9000029B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
US9211279B2 (en) Proline sulfonamide derivatives as orexin receptor antagonists
CN101687773B (zh) 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用
KR101839716B1 (ko) 오렉신 수용체 길항제로서의 (s)-(2-(6-클로로-7-메틸-1h-벤조[d]이미다졸-2-일)-2-메틸피롤리딘-1-일)(5-메톡시-2-(2h-1,2,3-트리아졸-2-일)페닐)메타논의 결정성 염 형태
CN105793257B (zh) 苯并咪唑环化合物的晶形及其用途
CA2828831C (en) Compounds and methods for the treatment of pain and other disorders
HK1225736A1 (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
JP2019524818A (ja) スルホニルピリジルtrp阻害剤
WO2020007977A1 (en) 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020007964A1 (en) 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) Benzimidazole-2-methyl-morpholine derivatives
HK1138566B (en) Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
JP2015166385A (ja) 疼痛および他の障害の処置のための化合物および方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171108

Address after: Swiss A Skei Weil

Patentee after: ACTELION PHARMACEUTICALS LTD.

Address before: Swiss A Skei Weil

Patentee before: Actelion Pharmaceuticals Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150708